Detalhe da pesquisa
1.
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
Blood
; 135(21): 1870-1881, 2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157281
2.
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.
Blood
; 123(21): 3296-304, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24723681
3.
Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.
Blood
; 120(8): 1633-46, 2012 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22623625
4.
Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Clin Cancer Res
; 30(3): 586-599, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992313
5.
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.
Clin Cancer Res
; 27(7): 2050-2060, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33441295
6.
TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
JCI Insight
; 3(4)2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467338
7.
Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
Oncoimmunology
; 6(6): e1320625, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28680755
8.
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).
Oncotarget
; 8(39): 65917-65931, 2017 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29029482
9.
Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.
Oncoimmunology
; 5(9): e1211221, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27757306
10.
T cell receptor mimic antibodies for cancer therapy.
Oncoimmunology
; 5(1): e1049803, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26942058
11.
Opportunities and challenges for TCR mimic antibodies in cancer therapy.
Expert Opin Biol Ther
; 16(8): 979-87, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27094818
12.
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Nat Biotechnol
; 33(10): 1079-86, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26389576
13.
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Cancer Cell
; 28(1): 15-28, 2015 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26175413
14.
Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Clin Cancer Res
; 20(15): 4036-46, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24850840
15.
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.
Cancer Discov
; 4(5): 578-91, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24550032
16.
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.
Sci Transl Med
; 5(176): 176ra33, 2013 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23486779